|
|
Volumn 311, Issue 22, 2014, Pages 2262-2263
|
|
WHO issues guidelines on HCV amid drug cost controversy
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BOCEPREVIR;
SIMEPREVIR;
SOFOSBUVIR;
TELAPREVIR;
COST EFFECTIVENESS ANALYSIS;
DRUG COST;
HEALTH CARE COST;
HEPATITIS C;
HEPATITIS C VIRUS;
HIGH RISK PATIENT;
HUMAN;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RESOURCE ALLOCATION;
SEROLOGY;
SHORT SURVEY;
SOCIOECONOMICS;
WORLD HEALTH ORGANIZATION;
ANTIVIRAL AGENTS;
DRUG COSTS;
HEPATITIS C;
HETEROCYCLIC COMPOUNDS, 3-RING;
HUMANS;
PRACTICE GUIDELINES AS TOPIC;
SULFONAMIDES;
URIDINE MONOPHOSPHATE;
WORLD HEALTH ORGANIZATION;
|
|
EID: 84902181691
PISSN: 00987484
EISSN: 15383598
Source Type: Journal
DOI: 10.1001/jama.2014.5277 Document Type: Short Survey |
|
Times cited : (11)
|
|
References (0)
|
